EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression

Jakob Albrethsen iD, Peter Busch Østergren, Pernille Badsberg Norup, Jens Sønksen, Mikkel Fode, Caroline Kistorp iD, Nikolai B Nordsborg, Sara Amalie Solheim, Jakob Mørkeberg, Katharina M Main, Anders Juul iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad291 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Jakob Albrethsen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Insulin, Prostatic Neoplasms, Testosterone. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Innovation Fund Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Serum insulin-like factor 3 (INSL3) is a Leydig cell biomarker, but little is known about the circulating concentration of INSL3 during hypothalamus-pituitary-testicular suppression.

Aim

To study the concomitant changes in serum concentrations of INSL3, testosterone, and LH during experimental and therapeutic testicular suppression.

Methods

We included serum samples from 3 different cohorts comprising subjects before and after testicular suppression: (1) 6 healthy young men who were treated with androgens (Sustanon, Aspen Pharma, Dublin, Ireland); 2) 10 transgender girls (male sex assigned at birth) who were treated with 3-monthly GnRH agonist injections (Leuprorelinacetat, Abacus Medicine, Copenhagen, Denmark); and (3) 55 patients with prostate cancer who were randomized to surgical castration (bilateral subcapsular orchiectomy) or treatment with GnRH agonist (Triptorelin, Ipsen Pharma, Kista, Sweden). Serum INSL3 and testosterone concentrations were quantified in stored serum samples using validated liquid chromatography-tandem mass spectrometry methodologies, and LH was measured by an ultrasensitive immunoassay.

Results

The circulating concentrations of INSL3, testosterone, and LH decreased during experimental testicular suppression in healthy young men by Sustanon injections and subsequently returned to baseline levels after release of suppression. All 3 hormones decreased during therapeutic hormonal hypothalamus-pituitary-testicular suppression in transgender girls and in patients with prostate cancer.

Conclusion

INSL3 resembles testosterone as a sensitive marker of testicular suppression and reflects Leydig cell function, also during exposure to exogenous testosterone. Serum INSL3 measurements may complement testosterone as a Leydig cell marker in male reproductive disorders, during therapeutic testicular suppression as well as in surveillance of illicit use of androgens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinProstatic NeoplasmsTestosteroneHumansMaleAndrogensGonadotropin-Releasing HormoneLeydig CellsLuteinizing HormoneProteinsTestisFemaleAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overTransgender Persons

Stichwörter der Autor:innen

INSL3LC-MS/MSgonadal suppressionprostate cancertransgender girls (male sex assigned at birth)

Substanzen

AndrogensGonadotropin-Releasing HormoneInsulinLeydig insulin-like proteinLuteinizing HormoneProteinsTestosterone

Autor:innen und Institutionen

  • Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark.
  • International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, 2100 Copenhagen, Denmark.
  • Department of Endocrinology, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark.
  • Department of Nutrition, Exercise and Sports, University of Copenhagen, 2100 Copenhagen, Denmark.
  • Science and Research, Anti Doping Denmark, 2660 Brøndby, Denmark.

ORCID-Profile: Jakob Albrethsen, Caroline Kistorp, Anders Juul

Förderung

  • Innovation Fund Denmark

Zitieren

APA

Albrethsen, J., Østergren, P. B., Norup, P. B., Sønksen, J., Fode, M., Kistorp, C., Nordsborg, N. B., Solheim, S. A., Mørkeberg, J., Main, K. M., & Juul, A. (2023). Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad291

Vancouver

Albrethsen J, Østergren PB, Norup PB, Sønksen J, Fode M, Kistorp C, et al. Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad291

BibTeX
@article{Albrethsen2023,
  author = {Albrethsen, Jakob and Østergren, Peter Busch and Norup, Pernille Badsberg and Sønksen, Jens and Fode, Mikkel and Kistorp, Caroline and Nordsborg, Nikolai B and Solheim, Sara Amalie and Mørkeberg, Jakob and Main, Katharina M and Juul, Anders},
  title = {Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad291}
}
Kostenlos starten →